Taro Pharmaceutical Industries Ltd.
TARO
TARO was delisted on the 21st of June, 2024.
78 hedge funds and large institutions have $262M invested in Taro Pharmaceutical Industries Ltd. in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 28 increasing their positions, 25 reducing their positions, and 11 closing their positions.
12% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 25
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 84 → 78 (-6)
17% less capital invested
Capital invested by funds: $315M → $262M (-$53.7M)
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $548K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$3.78M |
| 2 |
EP
Eversept Partners
New York
|
+$2.29M |
| 3 |
Renaissance Technologies
New York
|
+$2.18M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.35M |
| 5 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
+$1.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$2.41M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$2.09M |
| 3 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$1.59M |
| 4 |
CAM
Claret Asset Management
Montreal,
Quebec, Canada
|
-$1.2M |
| 5 |
Bank of New York Mellon
New York
|
-$1.16M |
TARO Hedge Fund Activity: Q3 2020 in Review
78 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q3 2020, worth a combined $262M — down 17% from $315M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of TARO and 5 opened new positions — a net loss of 6 holders — while 25 trimmed existing stakes and 28 added.
The largest buyer was Northern Trust, adding an estimated $3.78M. The largest seller was Citadel Advisors, cutting an estimated $2.41M.
- 78 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q3 2020, down from 84 in Q2 2020.
- Funds reported $262M of Taro Pharmaceutical Industries Ltd. stock for Q3 2020, down 17% quarter-over-quarter.
- 5 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q3 2020 and 11 closed out, a net change of -6 holders.
- The largest Taro Pharmaceutical Industries Ltd. buyer in Q3 2020 was Northern Trust, an estimated $3.78M added.
- The largest Taro Pharmaceutical Industries Ltd. seller in Q3 2020 was Citadel Advisors, an estimated $2.41M sold.
Based on aggregated 13F filings for Q3 2020.